For TP53 mutant AML, quantification of VAF, mutational burden, and distinguishing between monoallelic, biallelic, and multi-hit TP53 mutations provide important prognostic insights and may predict responses to targeted therapies. This evidence concerns the gene TP53 and acute myeloid leukemia.